Chronic Idiopathic Urticaria (CIU) Treatment Market Size
Market Size in USD Bn
CAGR8.2%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 8.2% |
| Market Concentration | High |
| Major Players | Taizhou Mabtech Pharmaceutical Co. Ltd., Celldex Therapeutics, Allakos, Novartis, GlaxoSmithKline and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Chronic Idiopathic Urticaria (CIU) Treatment Market Analysis
The Chronic Idiopathic Urticaria (CIU) treatment market is estimated to be valued at USD 16.36 Bn in 2025 and is expected to reach USD 28.2.40 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.2% from 2025 to 2032.
There is continuous development of innovative and effective drugs for treating chronic idiopathic urticaria. Furthermore, rising prevalence of chronic idiopathic urticaria worldwide due to increasing environmental pollution and allergens is expected to drive the demand for effective CIU treatments.